English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 847663 Online Users : 384
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
癌症研究所
陳立宗
--期刊論文
--圖書
--會議論文/會議摘要
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
國家衛生研究院 NHRI
>
癌症研究所
>
陳立宗
>
Browse By Title
Browse By Authors
Browse By Date
Browse By Data Type
Community Detail
Introduction:
NA
Loading...
Collection
期刊論文
[
327
/330]
圖書
[
1
/1]
會議論文/會議摘要
[
115
/179]
Siblings
于重元
[
19
/19]
劉柯俊
[
85
/98]
劉滄梧
[
119
/125]
劉界元(2003-2010)
[
3
/3]
夏和雄(1996-2012)
[
26
/31]
夏興國
[
51
/54]
姜乃榕
[
82
/94]
常慧如
[
39
/44]
張俊彥
[
234
/254]
張光裕
[
69
/79]
張憶壽
[
103
/106]
張文祥
[
52
/53]
張書銘
[
89
/91]
彭汪嘉康(1996-2007)
[
120
/126]
施能耀
[
37
/43]
李家惠
[
29
/29]
李岳倫
[
48
/49]
林素芳
[
32
/32]
楊奕馨
[
41
/42]
江士昇
[
88
/90]
沈哲宏
[
14
/16]
洪文俊
[
88
/88]
莊雙恩
[
82
/91]
蔡坤志
[
32
/34]
蔡慧珍
[
66
/71]
蘇勇曄
[
40
/40]
蘇振良
[
24
/25]
郭靜娟
[
71
/76]
陳尚鴻
[
45
/48]
陳振陽
[
72
/72]
陳美霞(2002-2009)
[
1
/1]
陳詩政
[
2
/2]
陳雅雯
[
38
/39]
黃智興
[
55
/55]
黃道揚
[
26
/26]
丁兆治(2000-2004)
[
5
/5]
其他
[
464
/471]
劉敏(1996-2007)
[
60
/62]
劉玫英(2004-2006)
[
2
/2]
吳成文(1996-2008)
[
53
/55]
曾思文(1997-2007)
[
4
/4]
李冠德(1997-2004)
[
4
/6]
林景太(1999-2007)
[
5
/5]
楊文光(1996-1999)
[
21
/21]
王全正(1996-2003)
[
4
/4]
莊聲宏(1997-2004)
[
11
/11]
詹宗晃(2000-2008)
[
2
/2]
賴基銘(2004-2008)
[
41
/47]
阮麗蓉(2000-2006)
[
6
/7]
陳俊叡(2003-2007)
[
6
/6]
馬彥英(1997-1999)
[
1
/1]
黃奇英(2005-2007)
[
9
/10]
Community Statistics
近3年內發表的文件:74(14.51%)
含全文筆數:443(86.86%)
文件下載次數統計
下載大於0次:443(100.00%)
下載大於100次:424(95.71%)
檔案下載總次數:176904(3.30%)
最後更新時間: 2024-11-28 13:36
Top Upload
Loading...
Top Download
Loading...
Recent Submissions
Pan-Asian adapted ESMO clinical pra...
Nivolumab plus chemotherapy in pati...
Survival of advanced/recurrent gast...
Topiramate suppresses peri-infarct ...
A phase 1 study of biweekly nab-pac...
Plain language summary of the FOENI...
Outcomes of post-immunotherapy dura...
Durvalumab or placebo plus gemcitab...
Impact of previous S-1 treatment on...
Chromatin remodeling-related PRDM1 ...
Jump to a point in the index:
(Choose year)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1985
1980
1975
1970
1960
1950
(Choose month)
January
February
March
April
May
June
July
August
September
October
November
December
Or type in a year:
Ordering With Most Recent First
Show Oldest First
Showing items 226-250 of 510. (21 Page(s) Totally)
<<
<
5
6
7
8
9
10
11
12
13
14
>
>>
View [
10
|
25
|
50
] records per page
Date
Title
Relation
2017-09
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P.
2017-09
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O.
2017-08
Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib
Clinical Cancer Research. 2017 Aug;23(16):4908-4918.
2017-08
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Cancer Chemotherapy and Pharmacology. 2017 Aug;80(2):307-315.
2017-07
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
Oncotarget. 2017 Jul;8(27):44121-44130.
2017-06-26
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018.
2017-06-26
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017.
2017-05-04
Chemotherapy in the management of pancreatic cancer
Pancreatic Cancer: With Special Focus on Topical Issues and Surgical Techniques. 2017 May 4:387-419.
2017-05
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis
British Journal of Cancer. 2017 May;116(10):1247-1253.
2017-05
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795.
2017-05
A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy
Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531.
2017-02
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations
Journal of Clinical Oncology. 2017 Feb;35(6):689-690.
2017-02
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)
Journal of Pathology. 2017 Feb;241(3):420-433.
2017-02
Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells
Oncology Reports. 2017 Feb;37(2):969-978.
2017-02
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417.
2017-02
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303.
2017-02
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2.
2017-02
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293.
2017-01
Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL
Blood. 2017 Jan;129(2):188-198.
2016-12
The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
Asia-Pacific Journal of Clinical Oncology. 2016 Dec;12(4):396-402.
2016-12
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD.
2016-12
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P.
2016-12
Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P.
2016-11-21
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
BMC Cancer. 2016 Nov 21;16:Article number 907.
2016-11
Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer
Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245.
Showing items 226-250 of 510. (21 Page(s) Totally)
<<
<
5
6
7
8
9
10
11
12
13
14
>
>>
View [
10
|
25
|
50
] records per page
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback